[go: up one dir, main page]

BR0315604A - Composição de liberação controlada para administração oral de drogas - Google Patents

Composição de liberação controlada para administração oral de drogas

Info

Publication number
BR0315604A
BR0315604A BR0315604-4A BR0315604A BR0315604A BR 0315604 A BR0315604 A BR 0315604A BR 0315604 A BR0315604 A BR 0315604A BR 0315604 A BR0315604 A BR 0315604A
Authority
BR
Brazil
Prior art keywords
release composition
controlled release
drug administration
oral drug
none given
Prior art date
Application number
BR0315604-4A
Other languages
English (en)
Inventor
Jong-Soo Woo
Moon-Hyuk Chi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR0315604A publication Critical patent/BR0315604A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO DE LIBERAçãO CONTROLADA PARA ADMINISTRAçãO ORAL DE DROGAS". Uma composição de liberação controlada para administração oral de uma droga, compreendendo a droga, uma mistura de alginato de sódio e goma xantana como um carreador para liberação controlada e uma mistura de hidroxipropil metilcelulose e alginato propileno glicol como um gel acelerador de hidratação, que é capaz de manter um nível constante de droga no sangue por 24 horas ou mais, devido ao fato que a razão de liberação de droga não segue ordem cinética e não significantemente varia com o grau de mobilidade gastrointestinal, devido a rápida hidratação do gel sem formar um núcleo não-gelificado.
BR0315604-4A 2002-10-23 2003-10-23 Composição de liberação controlada para administração oral de drogas BR0315604A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020020064940A KR100548925B1 (ko) 2002-10-23 2002-10-23 약물의 경구투여용 서방성 조성물
PCT/KR2003/002241 WO2004037290A1 (en) 2002-10-23 2003-10-23 Sustained release composition for oral administration of drugs

Publications (1)

Publication Number Publication Date
BR0315604A true BR0315604A (pt) 2005-08-23

Family

ID=36093911

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315604-4A BR0315604A (pt) 2002-10-23 2003-10-23 Composição de liberação controlada para administração oral de drogas

Country Status (19)

Country Link
US (1) US7704526B2 (pt)
EP (1) EP1413295B1 (pt)
JP (1) JP4177227B2 (pt)
KR (1) KR100548925B1 (pt)
CN (1) CN100342912C (pt)
AT (1) ATE380545T1 (pt)
AU (1) AU2003272118B2 (pt)
BR (1) BR0315604A (pt)
CA (1) CA2502731C (pt)
DE (1) DE60317993T2 (pt)
ES (1) ES2297078T3 (pt)
IL (1) IL167725A (pt)
MX (1) MXPA05004018A (pt)
NZ (1) NZ539192A (pt)
PL (1) PL375440A1 (pt)
RU (1) RU2295358C2 (pt)
UA (1) UA77123C2 (pt)
WO (1) WO2004037290A1 (pt)
ZA (1) ZA200503270B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100598326B1 (ko) * 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
KR100620241B1 (ko) * 2004-10-21 2006-09-19 한국유나이티드제약 주식회사 벤라팍신 염산염의 장기지속성 경구투여 조성물
KR101366764B1 (ko) 2005-05-31 2014-02-25 주식회사 씨티씨바이오 메실산독사조신 서방정의 제조방법
WO2007055329A1 (ja) * 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
CN101346135A (zh) * 2005-12-27 2009-01-14 莫诺索尔克斯有限公司 用于活性剂递送的已调节pH的膜
CN101129355B (zh) * 2007-08-03 2010-12-08 山东华信制药有限公司 一种洛伐他汀缓释片及其制备方法
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
PL226261B1 (pl) * 2008-12-31 2017-07-31 Univ Jagiellonski Kompozycja do przedłużonego uwalniania heparyny i zastosowanie żelu alginian-hydroksypropyloceluloza do przedłużonego uwalniania heparyny
US10137093B2 (en) 2011-08-16 2018-11-27 Cardiora Pty Ltd. Milrinone controlled-release formulation
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
WO2016101024A1 (en) 2014-12-22 2016-06-30 Baker Idi Heart & Diabetes Institute Holdings Limited Method of treatment
CN107050419A (zh) * 2017-04-20 2017-08-18 上药东英（江苏）药业有限公司 一种培哚普利及其盐的渗透泵片及其制备方法
EP3501503A1 (en) * 2017-12-22 2019-06-26 Cosmo Technologies Ltd. Solid delivery composition
CN109288808A (zh) * 2018-11-13 2019-02-01 华东理工大学 一种溶出度高的植物纤维素胶囊

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4765984A (en) * 1986-01-22 1988-08-23 Colgate-Palmolive Company Stable single unit dose oral product
US4792452A (en) 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5128143A (en) * 1988-09-19 1992-07-07 Edward Mendell Co., Inc. Sustained release excipient and tablet formulation
US5415872A (en) * 1992-06-22 1995-05-16 Digestive Care Inc. Compositions of gastric acid-resistant microspheres containing salts of bile acids
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
AU772891B2 (en) * 1998-12-11 2004-05-13 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
KR20010089887A (ko) * 1999-10-20 2001-10-12 야스이 쇼사꾸 수성의약품 조성물
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
WO2001087270A2 (en) * 2000-05-12 2001-11-22 Pharmacia & Upjohn Company Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
US6465014B1 (en) * 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition

Also Published As

Publication number Publication date
CN100342912C (zh) 2007-10-17
CA2502731A1 (en) 2004-05-06
AU2003272118A1 (en) 2004-05-13
PL375440A1 (en) 2005-11-28
JP4177227B2 (ja) 2008-11-05
CA2502731C (en) 2009-03-17
ZA200503270B (en) 2006-10-25
KR100548925B1 (ko) 2006-02-02
WO2004037290A1 (en) 2004-05-06
DE60317993D1 (de) 2008-01-24
ES2297078T3 (es) 2008-05-01
KR20040036130A (ko) 2004-04-30
UA77123C2 (en) 2006-10-16
DE60317993T2 (de) 2008-04-17
EP1413295B1 (en) 2007-12-12
US7704526B2 (en) 2010-04-27
JP2004143175A (ja) 2004-05-20
IL167725A (en) 2010-05-31
US20040081693A1 (en) 2004-04-29
CN1741819A (zh) 2006-03-01
RU2295358C2 (ru) 2007-03-20
MXPA05004018A (es) 2007-08-30
ATE380545T1 (de) 2007-12-15
RU2005115483A (ru) 2005-11-20
EP1413295A1 (en) 2004-04-28
NZ539192A (en) 2006-11-30
AU2003272118B2 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
BR0315604A (pt) Composição de liberação controlada para administração oral de drogas
ES2156603T3 (es) Medicamentos a base de una mezcla sinergetica de metronidazol y de clindamicina.
HUP0101237A1 (hu) Elnyújtott kioldódású gyógyszerkészítmények
NO20011471D0 (no) Nye orale vedvarende frigivelsesformuleringer
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
AR023972A1 (es) Composiciones de medicamentos a base de compuestos anticolinergicamente activos y beta-mimeticos
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
NL2000281A1 (nl) Vaste farmaceutische samenstellingen die pregabaline bevatten.
ATE450252T1 (de) Arzneimittel-mikroteilchen
AR032293A1 (es) Estuche farmaceutico
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
AR109644A2 (es) Pradofloxacina y composición farmacéutica para el tratamiento sistémico de enfermedades bacterianas en la cavidad bucal
HRP20080117A2 (en) Pharmaceutical composition for modified release insulin sensitiser
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
CY1111607T1 (el) Ενωσεις 1-φαινυλο-2-διμεθυλαμινομεθυλο-κυκλοεξανιου για τη θεραπεια καταθλιπτικων συμπτωματικων, πονου και ακρατειας ουρων
PA8576301A1 (es) Capsulas para la higiene bucal
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
SI1140168T1 (en) Vaccination against cancer
BR0315247A (pt) Composição, composição farmacêutica, método de tratamento para uma doença proliferativa celular, e, kit
CY1105317T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
DE60320039D1 (de) Tramadol-formulierungen mit verzögerter freisetzung und 24-stunden-wirksamkeit
ATE455540T1 (de) Orale dosierform für die kontrollierte arzneimittelfreisetzung
AU2002256775A1 (en) Therapeutic method for inducing tolerance
ATE368465T1 (de) Orale diätzusammensetzung, enthaltend konjugierte linolsäure und coffein

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 47/00, A61P 9/00, A61P 9/12

Ipc: A61K 47/00 (2011.01), A61P 9/00 (2011.01), A61P 9/

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO OBSTACULO ADMINSTRATIVO E DEVOLVIDO O PRAZO DE 27 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/2004 .

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A E 12A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.